Akebia Therapeutics (NASDAQ:AKBA) stock had its “buy” rating restated by research analysts at Nomura in a report released on Monday, Analyst Ratings.Net reports. They currently have a $39.00 price objective on the stock. Nomura‘s target price indicates a potential upside of 131.32% from the stock’s previous close. Akebia Therapeutics Inc (NASDAQ:AKBA) shares after opening at $19.35 moved to $23.32 on last trade day and at the end of the day closed at $21.14 Company price to cash ratio as 13.18. Akebia Therapeutics Inc (NASDAQ:AKBA) showed a positive weekly performance of 17.44%.
Leerink Swann started coverage on shares of Kindred Biosciences Inc (NYSE:KIN). Leerink Swann issued an outperform rating and a $32.00 target price on the stock. Kindred Biosciences Inc (NASDAQ:KIN) shares advanced 11.80% in last trading session and ended the day on $16.39. KIN return on equity ratio is recorded as -31.40% and its return on assets is -24.00%.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) was a big mover last session, as its shares rose almost 29% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This breaks the trend of the company, as it is now trading above the volatile price range of $4.25 to $5.10 in the past one-month timeframe. RXi Pharmaceuticals Corp (NASDAQ:RXII) shares moved up 6.27% in last trading session and was closed at $3.47, while trading in range of $3.29 – 3.58. RXi Pharmaceuticals Corp (NASDAQ:RXII) year to date (YTD) performance is 19.66%.
Neo Stem, Inc. (NASDAQ: NBS ) a leader in the emerging cellular therapy industry announced today that it has entered into a definitive agreement to acquire California Stem Cell, Inc. (“CSC”), an Irvine, California based stem cell biotechnology company. As a result of this acquisition, Neo Stem plans to initiate a pivotal Phase 3 trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence. Neo Stem Inc (NASDAQ:NBS) weekly performance is 0.15%. On last trading day company shares ended up $6.79. Neo Stem Inc (NASDAQ:NBS) distance from 50-day simple moving average (SMA50) is -4.62%. Analysts mean target price for the company is $19.75.